Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Ono/BMS Settles PD-1/PD-L1 Patent Row with Dana-Farber
April 10, 2023
- Generic Shipment Price Rate Likely Rose 1.5% for FY2023 Revision, Weighing on Wholesalers
April 10, 2023
- Sanofi Discontinues Sales of Allegra Dry Syrup in Japan
April 10, 2023
- Insud’s Oral Contraceptive Filed in South Korea: ASKA
April 10, 2023
- Japan Ethical Drug Sales Up 0.6% in February: Crecon
April 10, 2023
- Lenvima/Keytruda Combo Fails in 1st-Line Melanoma Study
April 10, 2023
- JCR, Sumitomo Sign Copromotion Pact for Izcargo in Japan
April 7, 2023
- Japan Pharma Sales Up 1.3% in FY2022: Encise
April 7, 2023
- Kissei’s ITP Med Tavalisse Now Available in Japan
April 7, 2023
- Major Renovation at Eisai’s Tsukuba Lab Completed
April 7, 2023
- Kowa Kicks Off Another PIII for Ripasudil for Fuchs Endothelial Corneal Dystrophy
April 7, 2023
- MSD Japan Nets 24% Growth in 2022 on Lagevrio, Keytruda; President Wary of Further Re-Pricing
April 6, 2023
- Macrocyclic Peptide Hits Milestone in Joint R&D: PeptiDream/Bayer
April 6, 2023
- Avastin Biosimilar Grabs Ovarian Cancer Nod: Nippon Kayaku/Celltrion
April 6, 2023
- Sumitomo to Combine US Subsidiaries as It Looks towards Post-Latuda Era
April 5, 2023
- Lecanemab Use at MCI Stage Might Have Larger Impact on Delaying AD Progression: Eisai
April 5, 2023
- Padcev/Keytruda Combo Wins US Accelerated Nod for First-Line Bladder Cancer: Astellas
April 5, 2023
- Xocova Nabs Fast-Track Tag in US: Shionogi
April 5, 2023
- Silgard 9 Now Available under NIP; MSD Renews Call for Cervical Cancer Prevention
April 4, 2023
- Insmed Taps Ex-Gilead Director Makoto Nakamura as New Japan Chief
April 4, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…